- Home
- IMVT
IMVT
Immunovant Inc.
as 05-09-2025 3:37pm EST
Immunovant Inc is a clinical-stage biopharmaceutical company. It is focused on enabling normal lives for patients with autoimmune diseases. The company's product includes batoclimab and IMVT-1402 targets the neonatal Fc receptor (FcRn).
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 2.5B | IPO Year: | N/A |
| Target Price: | $40.14 | AVG Volume (30 days): | 1.4M |
| Analyst Decision: | Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.62 | EPS Growth: | N/A |
| 52 Week Low/High: | $12.72 - $34.47 | Next Earning Date: | 05-28-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | 108.88% | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Immunovant Inc. (IMVT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Geffner Michael | IMVT | Chief Medical Officer | Apr 23 '25 | Sell | $14.79 | 2,349 | $34,741.71 | 225,370 | |
| Stout Jay S | IMVT | Chief Technology Officer | Apr 23 '25 | Sell | $14.79 | 1,925 | $28,470.75 | 209,243 | |
| Barnett Eva Renee | IMVT | Chief Financial Officer | Apr 16 '25 | Sell | $14.89 | 2,993 | $44,565.77 | 396,774 | |
| Salzmann Peter | IMVT | Chief Executive Officer | Apr 16 '25 | Sell | $14.89 | 8,321 | $123,899.69 | 1,178,191 | |
| Barnett Eva Renee | IMVT | Chief Financial Officer | Apr 9 '25 | Sell | $12.99 | 11,063 | $143,708.37 | 396,774 | |
| Salzmann Peter | IMVT | Chief Executive Officer | Apr 9 '25 | Sell | $12.99 | 28,094 | $364,941.06 | 1,178,191 | |
| Geffner Michael | IMVT | Chief Medical Officer | Apr 9 '25 | Sell | $12.99 | 6,169 | $80,135.31 | 225,370 | |
| Stout Jay S | IMVT | Chief Technology Officer | Apr 9 '25 | Sell | $12.99 | 5,004 | $65,001.96 | 209,243 | |
| Fromkin Andrew J. | IMVT | Director | Mar 7 '25 | Sell | $19.74 | 8,000 | $156,768.96 | 93,297 | |
| Macias William L. | IMVT | Chief Medical Officer | Feb 19 '25 | Sell | $20.86 | 2,055 | $42,867.30 | 357,353 |
Latest Immunovant Inc. News
IMVT Breaking Stock News: Dive into IMVT Ticker-Specific Updates for Smart Investing
Insider Monkey
9 hours ago
Is Immunovant, Inc. (IMVT) The Best Stock That Will Bounce Back?
MT Newswires
17 days ago
UBS Downgrades Immunovant to Neutral, Price Target is $17
BioPharma Dive
17 days ago
Akeso claims another PD-1/VEGF win; FDA requests more data from Novavax
Investor's Business Daily
18 days ago
Immunovant Dives On Its C-Suite Sweep, Narrowed Plans For Leading Drug
MT Newswires
18 days ago
Immunovant Names New CEO, CFO
GlobeNewswire
18 days ago
Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren’s Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402
Argus Research
25 days ago
Daily – Vickers Top Buyers & Sellers for 04/14/2025
Insider Monkey
a month ago
Is Immunovant, Inc. (IMVT) the Best Low Cost Stock to Buy According to Billionaires?
Compare IMVT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IMVT Immunovant Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.